Enanta Pharmaceuticals announced that new preclinical data from Enanta’s wholly-owned development programs for hepatitis B virus, or HBV, and non-alcoholic steatohepatitis, or NASH, will be presented at The International Liver Congress. Jay Luly, President and CEO of Enanta, said, “Our extensive scientific research provides us the knowledge and confidence to move forward our best candidates with the highest likelihood of success. We look forward to announcing clinical results of EDP-305 in our ARGON-1 Phase 2 study in NASH patients in the third quarter and to initiating a phase 1 study with EDP-514 during the second half of 2019.”
https://thefly.com/landingPageNews.php?id=2891447
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.